Healthcare / BiotechnologyNasdaqGS
$9.71
-0.20 (-2.02%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-109.6M · quality 52.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
41/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$508M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-27.7%
↓Gross Margin
N/A
•Debt/Equity
0.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2019–2025 · 6 años de histórico normalizado
Revenue CAGR
+51.8%
FCF CAGR
—
FCF margin
-128.6%
FCF / Net income
0.78x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $85.2M · net income $-140.1M · FCF $-109.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | $85.2M | $85.2M | $37000.00 | $20.7M | $3.1M | $18.0M | $13.4M | $7.0M |
| Net Income | $-140.1M | $-140.1M | $-160.9M | $-100.8M | $-107.5M | $-71.3M | $-56.7M | $-49.3M |
| EBITDA | $-151.9M | $-151.9M | $-181.1M | $-107.1M | $-106.2M | $-69.8M | $-55.2M | $-49.8M |
| EPS | — | — | -2.98 | -2.58 | -3.32 | -2.57 | — | — |
| Operating Margin | -187.2% | -187.2% | -507678.4% | -544.6% | -3516.5% | -395.5% | -424.0% | -729.4% |
| Net Margin | -164.4% | -164.4% | -434778.4% | -486.6% | -3435.4% | -395.4% | -424.3% | -708.4% |
| Balance Sheet | ||||||||
| Debt/Equity | 0.04 | 0.04 | 0.05 | 0.05 | 0.07 | — | — | — |
| Current Ratio | 9.34 | 9.34 | — | — | — | — | — | — |
| Cash Flow | ||||||||
| Free Cash Flow | $-109.6M | $-109.6M | $-138.4M | $-78.6M | $-98.2M | $-78.2M | $-51.9M | $-39.9M |
| Returns | ||||||||
| ROE | -27.7% | -27.7% | -31.5% | -32.8% | -46.5% | -22.3% | -22.1% | 67.6% |
| Valuation | ||||||||
| P/B | 1.11 | 1.11 | 0.63 | 2.49 | 3.24 | — | — | — |
| Growth & Yield | ||||||||
| Revenue Growth | 230194.6% | 230194.6% | -99.8% | 562.3% | — | 35.0% | 92.0% | — |
| EPS Growth | — | — | -15.5% | 22.3% | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+168.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.98 → n/d
Residual
+168.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.